Ranibizumab Versus Aflibercept for CRVO in Young Patients.
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in
treatment of macular edema resulting from non ischemic central retinal vein occlusion in
patients younger than 5o years old